DNLI
Denali Therapeutics Inc.Marquee-fund ownership over time
This quarter's activity
New positions opened
None.
Current holders
Sorted by tenure (longest first)| Fund | First disclosed | Held | Entry price | Latest close | Return on entry |
|---|---|---|---|---|---|
| Citadel Advisors | Q3 2024(8Q snapshot) | 7Q | $22 | $18 | -18% |
| Millennium Management | Q3 2024(8Q snapshot) | 7Q | $22 | $18 | -18% |
| AQR Capital Management re-entered | Q4 2024(8Q snapshot) | 6Q | $28 | $18 | -35% |
“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.
Past holders
Funds that exited at some point| Fund | Last entry | Exited | Entry → Exit | Return |
|---|---|---|---|---|
| Two Sigma Investments | Q3 2024 | Q2 2026 | → $19 | -17% |
| Point72 Asset Management 2× in & out | Q3 2025 | Q2 2026 | → $19 | +29% |
| Renaissance Technologies | Q2 2025 | Q2 2026 | → $19 | +39% |
| D.E. Shaw 3× in & out | Q2 2025 | Q3 2025 | → $14 | +2% |
| Bridgewater Associates 2× in & out | Q1 2023 | Q2 2023 | → $28 | -7% |
Insider activity
Form 4 — officers, directors, 10%+ ownersFiled within two business days of each transaction by anyone with material insider status at Denali Therapeutics Inc.. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.
30d / 90d windows measured from Jun 5, 2026 — the most recent Form 4 on file — not from today.
- Form 40001189130-26-000005Jun 5, 2026
- Form 40001478007-26-000002Jun 5, 2026
- Form 40001666236-26-000015Jun 5, 2026
- Form 40001578200-26-000004Jun 5, 2026
- Form 40001797826-26-000002Jun 5, 2026
- Form 40001816206-26-000003Jun 5, 2026
- Form 40001754371-26-000002Jun 5, 2026
- Form 40001193125-26-259680Jun 5, 2026
- Form 40001724310-26-000004Jan 8, 2026
- Form 40001724311-26-000005Jan 8, 2026
- Form 40001724311-26-000001Jan 5, 2026
- Form 40001724310-26-000001Jan 5, 2026
- Form 40001193125-25-319291Dec 15, 2025
- Form 40001816206-25-000007Nov 6, 2025
- Form 40001724310-25-000005Sep 5, 2025
Fundamentals
XBRL · Denali Therapeutics Inc.Annual figures sourced directly from Denali Therapeutics Inc.'s 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.
Recent SEC filings
10-K · 10-Q · 8-K · 13D/G · proxyThe most recent material filings for Denali Therapeutics Inc. — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.
- 8-KMaterial eventJun 4, 2026
- 8-KMaterial eventMay 22, 2026
- 10-QQuarterly reportMay 7, 2026
- 8-KMaterial eventMay 7, 2026
- DEF 14AProxy statementApr 21, 2026
- 8-KMaterial eventApr 3, 2026
- 8-KMaterial eventMar 31, 2026
- 8-KMaterial eventMar 25, 2026
- 10-KAnnual reportFeb 26, 2026
- 8-KMaterial eventFeb 26, 2026
- 8-KMaterial eventJan 6, 2026
- 8-KMaterial eventDec 10, 2025
- 8-KMaterial eventDec 4, 2025
- 8-KMaterial eventDec 4, 2025
- 10-QQuarterly reportNov 6, 2025
Trade history
Every open→close lifecycle across tracked funds| Fund | Open date | Close date | Open price | Close price / current | Return |
|---|---|---|---|---|---|
| AQR Capital Management | Q3 2025 | open | $14 | $18 | +27% |
| Point72 Asset Management | Q3 2025 | Q2 2026 | $14 | $19 | +29% |
| D.E. Shaw | Q2 2025 | Q3 2025 | $14 | $14 | +2% |
| Renaissance Technologies | Q2 2025 | Q2 2026 | $14 | $19 | +39% |
| AQR Capital Management | Q4 2024 | Q1 2025 | $28 | $21 | -25% |
| Citadel Advisors | Q3 2024 | open | $22 | $18 | -18% |
| Two Sigma Investments | Q3 2024 | Q2 2026 | $22 | $19 | -17% |
| D.E. Shaw | Q3 2024 | Q4 2024 | $22 | $28 | +27% |
| D.E. Shaw | Q3 2024 | Q3 2025 | $0.00 | — | +0% |
| Millennium Management | Q3 2024 | open | $22 | $18 | -18% |
| Point72 Asset Management | Q3 2024 | Q2 2025 | $22 | $14 | -37% |
| Bridgewater Associates | Q1 2023 | Q2 2023 | $30 | $28 | -7% |
| Bridgewater Associates | Q2 2022 | Q4 2022 | $23 | $30 | +33% |
- Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
- Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
- “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
- Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
- Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.